Cargando…
Targeting Cbl-b in cancer immunotherapy
Cancer immunotherapy with immune-checkpoint blockade has improved the outcomes of patients with various malignancies, yet a majority do not benefit or develop resistance. To address this unmet need, efforts across the field are targeting additional coinhibitory receptors, costimulatory proteins, and...
Autores principales: | Augustin, Ryan C., Bao, Riyue, Luke, Jason J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906388/ https://www.ncbi.nlm.nih.gov/pubmed/36750253 http://dx.doi.org/10.1136/jitc-2022-006007 |
Ejemplares similares
-
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
por: Augustin, Ryan C., et al.
Publicado: (2022) -
Development of a personalized cellular ex-vivo cbl-b silencing cancer immunotherapy
por: Lametschwandtner, Guenther, et al.
Publicado: (2014) -
Releasing the Brake: Targeting Cbl-b to Enhance Lymphocyte Effector Functions
por: Wallner, Stephanie, et al.
Publicado: (2012) -
Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types
por: Bao, Riyue, et al.
Publicado: (2020) -
Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency
por: Huemer, Martina, et al.
Publicado: (2016)